% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell Feb 17, 2013 5:22 PM Flag

    GDC-0973: Phase III started 02/11/2013

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: GDC-0973, RG7421 (formerly XL518)
    Found at BioCentury website

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Every time I see a post on GDC 0973, I think back to Ohad Hammers article. More specifically this paragraph-

      "Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche."


      Sentiment: Strong Buy

    • I hope Exelixis gets a milestone for this.

      Sentiment: Strong Buy

5.49-0.01(-0.18%)Nov 25 4:00 PMEST